Anika Therapeutics, Inc. (ANIK)
After hours:
| Previous close | 25.98 |
| Open | 26.09 |
| Bid | 25.88 x 100 |
| Ask | 26.22 x 100 |
| Day's range | 25.95 - 26.47 |
| 52-week range | 16.54 - 28.67 |
| Volume | |
| Avg. volume | 57,635 |
| Market cap | 379.272M |
| Beta (5Y monthly) | 0.84 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.24 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 31.00 |
GlobeNewswireAnika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on June 3, 2024, Anika granted: (i) non-statutory stock options (“Options”) covering 96,525 shares of common stock at a per share exercise price of $29.35, which equaled 110% of the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, and (ii) restricted stock units (
- GlobeNewswire
Anika Enters into Cooperation Agreement with Caligan Partners
Appoints Joseph Capper and William Jellison to Board of DirectorsAnnounces New $40 Million Share Repurchase Program BEDFORD, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has entered into a cooperation agreement with Caligan Partners LP (“Caligan”). As part of the agreement, Joseph Capper, CEO of MIMEDX, and William Jellison, former CFO of Stryker, have been appointed
Simply Wall St.Anika Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Anika Therapeutics ( NASDAQ:ANIK ) First Quarter 2024 Results Key Financial Results Revenue: US$40.5m (up 6.9% from 1Q...
